表紙
市場調查報告書

癌症免疫療法的全球市場:需求分析、機會評估

Global Immuno-Oncology Market Demand Analysis & Opportunity Evaluation, 2019-2027

出版商 Research Nester 商品編碼 915927
出版日期 內容資訊 英文 189 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫療法的全球市場:需求分析、機會評估 Global Immuno-Oncology Market Demand Analysis & Opportunity Evaluation, 2019-2027
出版日期: 2019年10月19日內容資訊: 英文 189 Pages
簡介

全球癌症免疫療法市場,2018年價值538億5,948萬美元,至2027年以12.68%的年複合成長率成長到1,572億3,048萬美元的市場規模。各地區中,2018年獲得世界佔有率的48.13%成為最大市場的北美預計今後也將維持其優勢。

本報告提供全球癌症免疫療法市場調查,市場概要,市場趨勢,各產品、給藥途徑、終端用戶、地區的市場規模的變化與預測,市場成長要素及課題分析,開發平台及臨床實驗趨勢,法規環境,風險分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

  • 簡介
  • 市場定義與市場概要
  • 產品定義
  • 調查目的
  • 摘要整理
  • 癌症免疫療法:市場動態
  • 市場成長要素
  • 市場課題
  • 市場趨勢
  • 市場機會
  • 產業分析
  • 流行病學分析
  • 癌症免疫療法聯合治療的調查
  • 開發平台、臨床實驗分析
  • 政策、法規環境
  • 風險分析
  • 全球癌症免疫療法市場
  • 市場概要 - 市場規模的變化與預測
  • 市場區隔:各產品
  • 市場區隔:各給藥途徑
  • 市場區隔:各終端用戶
  • 市場區隔:各地區
  • 競爭情形
  • 企業的市場定位
  • 主要企業的簡介
  • F. Hoffmann-La Roche Ltd
  • Merck & Company, Inc.
  • AstraZeneca Plc.
  • Novartis
  • Amgen Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen
  • GlaxoSmithKline plc.
  • Strategic Recommendations
目錄

The global immuno-oncology treatment market reached USD 53,859.48 million in 2018 and is expected to reach USD 157,230.48 million by 2027, by registering a CAGR of 12.68%, across the globe. This is primarily attributed to the rising concerns over hospital acquired infections across the globe.

North America captured a share of 48.13% in the year 2018 and is expected to dominate the market, over the forecast period. The growth in the region can be attributed to increase in investments towards healthcare from government and private entities to maintain the highest quality of care offered in healthcare facilities. The US is the major country driving the growth in the region, reaching a market value of USD 24,040.00 million in 2018 and is expected to grow at a CAGR of 13.14% over the forecast period i.e. 2020-2027. On the back of rising adoption of innovative treatment modalities focused on personalized medicine, it is expected to result in the market growth over the forecast period.

Availability of advanced diagnostic products that are capable of effectively diagnosing rare cancers are resulting in increasing number of people availing early treatment. The Asia Pacific region captured a market size of USD 10,560.34 million in the year 2018 and is expected to reach USD 32,498.22 million by 2027, with a CAGR of 13.32%. The market is primarily led by the demand from China, with a market of USD 4,199.90 million in the year 2018, and it is expected to grow at a CAGR of 14.54%. With the rising availability of advanced pharmaceuticals in this region, with rising number of products being approved in countries such as China, Japan, & India, to address the growing number of cancer patients in this region, the demand for immuno-oncology treatment products in this region is expected to witness a rapid growth over the forecast period.

Europe is expected to reach a market size of USD 36,620.08 million by 2027. It has been observed that with the availability of innovative treatment modalities, there has been a shift in treatment preferences from conventionally prescribed chemotherapy products to advanced and highly targeted treatment products. Although these products are relatively higher priced, there is an increasing number of patients opting for these products as along with a superior mode of action providing a faster recovery, they also enable a better quality of life during the treatment course with reduced side effects. Over the recent years, it has been observed that the European Union has been increasingly approving large number of immuno-oncology products such as cellular immunotherapy and immune checkpoint inhibitors. Although the presence of biosimilars in this region have affected the revenue recognition of certain products (Rituximab), this region is expected to generate a steady demand for advanced pharmaceutical products.

On the basis of segmentation by administration, the market is divided into standalone and combination therapies from which combination therapies is presently capturing a vast majority of the market. A large number of approved products are being investigated with various combinations of other immunotherapy products or else chemotherapy drugs. This is recommended in cases when the cancer has either spread to other regions of the body or else the healthcare provided opts for a highly aggressive treatment method. However, increasing number of drugs are being studied and approved as standalone therapies especially targeting benign tumors.

On the basis of end user, the market is segmented into hospitals, ambulatory surgical centers, clinics, and others. The hospitals segment captured the largest market with USD 38,075.29 million in 2018 and is expected to reach USD 109,482.05 million by 2027 with a CAGR of 12.50% over the forecast period. This can be attributed to the high number of patients encountered by hospitals and large facilities in comparison to smaller facilities such as clinics. Some of the largest players in this market are Roche, Merck, Amgen, Janssen, Eli Lilly and Novartis

Table of Contents

  • Introduction
  • Market Definition and Market Lineage Outlook
  • Product Definition
  • Research Objective
  • Research Methodology
  • Executive Summary
  • Market Dynamics of Global Immuno-Oncology Market
  • Market Drivers
  • Market Challenges
  • Market Trends
  • Opportunities
  • Industry Analysis
  • Epidemiology Analysis
  • Cancer Immunotherapy-based Combination Studies
  • Pipeline & Clinical Trial Analysis
  • Policy & Regulatory Landscape
  • Risk Analysis
  • Global Immuno-oncology Market
  • Market Overview - Market Size and Forecast, 2018-2027
  • Market Segmentation by:
  • Product
  • Administration
  • End User
  • Region
  • Competitive Landscape
  • Competitive Positioning
  • Company Profiles of top players
  • F. Hoffmann-La Roche Ltd
  • Merck & Company, Inc.
  • AstraZeneca Plc.
  • Novartis
  • Amgen Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Janssen
  • GlaxoSmithKline plc.
  • Strategic Recommendations
Back to Top